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Neurobiology of Disease

Enhancing Astrocytic Lysosome Biogenesis Facilitates A␤
Clearance and Attenuates Amyloid Plaque Pathogenesis
Qingli Xiao,1 Ping Yan,1 Xiucui Ma,2,3 Haiyan Liu,2 Ronaldo Perez,1 Alec Zhu,1 Ernesto Gonzales,1 Jack M. Burchett,1
Dorothy R. Schuler,1 John R. Cirrito,1 Abhinav Diwan,2,3* and Jin-Moo Lee1*
1

Department of Neurology and the Hope Center for Neurological Disorders and 2Division of Cardiology and Center for Cardiovascular Research,
Washington University School of Medicine, St. Louis, Missouri 63110, and 3John Cochran VA Medical Center, St. Louis, Missouri 63108

In sporadic Alzheimer’s disease (AD), impaired A␤ removal contributes to elevated extracellular A␤ levels that drive amyloid plaque
pathogenesis. Extracellular proteolysis, export across the blood– brain barrier, and cellular uptake facilitate physiologic A␤ clearance.
Astrocytes can take up and degrade A␤, but it remains unclear whether this function is insufficient in AD or can be enhanced to accelerate
A␤ removal. Additionally, age-related dysfunction of lysosomes, the major degradative organelles wherein A␤ localizes after uptake, has
been implicated in amyloid plaque pathogenesis. We tested the hypothesis that enhancing lysosomal function in astrocytes with transcription factor EB (TFEB), a master regulator of lysosome biogenesis, would promote A␤ uptake and catabolism and attenuate plaque
pathogenesis. Exogenous TFEB localized to the nucleus with transcriptional induction of lysosomal biogenesis and function in vitro. This
resulted in significantly accelerated uptake of exogenously applied A␤42, with increased localization to and degradation within lysosomes in C17.2 cells and primary astrocytes, indicating that TFEB is sufficient to coordinately enhance uptake, trafficking, and degradation of A␤. Stereotactic injection of adeno-associated viral particles carrying TFEB driven by a glial fibrillary acidic protein promoter was
used to achieve astrocyte-specific expression in the hippocampus of APP/PS1 transgenic mice. Exogenous TFEB localized to astrocyte
nuclei and enhanced lysosome function, resulting in reduced A␤ levels and shortened half-life in the brain interstitial fluid and reduced
amyloid plaque load in the hippocampus compared with control virus-injected mice. Therefore, activation of TFEB in astrocytes is an
effective strategy to restore adequate A␤ removal and counter amyloid plaque pathogenesis in AD.
Key words: Alzheimer’s disease; amyloid; astrocytes; lysosomes; TFEB

Introduction
Astrocytes are the most abundant cell type in the brain and play a
critical role in maintaining synaptic transmission and neuronal
health in homeostasis (Eroglu and Barres, 2010). Astrocytes are
activated in response to injury, with neurodegeneration (Barres,
2008), and in preclinical stages of Alzheimer’s disease (AD;
Schipper et al., 2006; Owen et al., 2009; Carter et al., 2012). Activated astrocytes surround amyloid plaques and neurofibrillary
tangles, which are the neuropathological hallmarks of advanced
AD (Funato et al., 1998; Nagele et al., 2003). Interestingly, in
these studies, astrocytes demonstrate immunoreactivity for amyloid material, and experimental observations confirm that as-
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trocytes can take up amyloid plaques and precursor A␤ peptides
in animal models of AD (Wyss-Coray et al., 2003; Koistinaho et
al., 2004). Despite these intriguing observations, the role of astrocytes in AD pathogenesis is under studied.
In AD, an imbalance between the production and degradation
of A␤ peptides drives increased extracellular levels in the interstitial fluid (ISF; Hardy and Selkoe, 2002) resulting in their
concentration-dependent oligomerization and deposition as amyloid plaques (Lomakin et al., 1997). Recent studies implicate
impaired A␤ removal as the dominant underlying mechanism in
individuals with the more common sporadic forms of AD
(Mawuenyega et al., 2010). Insights from animal models indicate
that in addition to extracellular proteolysis and transport across
the blood– brain barrier, A␤ can be taken up by astrocytes (WyssCoray et al., 2003; Koistinaho et al., 2004) and microglia (Mandrekar et al., 2009). We have observed that impairing astrocyte
activation by ablation of intermediate filament proteins, glial
fibrillary acidic protein (GFAP) and vimentin, results in increased plaque load (Kraft et al., 2013) pointing to a prominent
role for activated astrocytes in countering amyloid pathogenesis.
However, whether astrocyte function is inadequate (Wyss-Coray
et al., 2003), and therefore needs to be stimulated to accelerate
amyloid removal, remains unknown.
A␤ is taken up and trafficked to the lysosomes for degradation
in astrocytes (Basak et al., 2012). Impairment of lysosome func-
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tion with aging (Kato et al., 1998; Cuervo and Dice, 2000; Wolfe
et al., 2013), or with loss of presenilin, as observed in familial AD,
(Lee et al., 2010; Coen et al., 2012) has been implicated in AD
pathogenesis. It is suspected to be the underlying mechanism for
accumulation of A␤ and phagocytosed amyloid material within
astrocytes (Funato et al., 1998; Wyss-Coray et al., 2003), which
may paradoxically promote amyloid plaque progression (Nagele
et al., 2003). Recent studies demonstrate that activation of ubiquitously expressed transcription factor EB (TFEB) coordinately
stimulates lysosome biogenesis and cellular trafficking pathways
to promote breakdown of lipids and proteins to generate nutrients (Sardiello et al., 2009; Settembre et al., 2011, 2013b) and
remove abnormal aggregates in lysosome storage disorders
(Settembre et al., 2013a). In this study, we evaluated whether
targeted expression of TFEB in astrocytes stimulates uptake and
lysosomal degradation of A␤ to reduce ISF A␤ levels and attenuate amyloid plaque pathogenesis, in a mouse model of AD.

Materials and Methods
Reagents. A␤1– 42 was purchased from American Peptide; FAM-A␤42
from AnaSpec; LysoTracker Red DND-99 from Invitrogen; and trifluoroacetic acid, 1,1,1,3,3,3-hexafluoro-2-propanol, bafilomycin A1, heparin, biotin-labeled transferrin, and Dynasore from Sigma.
A␤ preparation. A␤42 was prepared as described previously (Hu et al.,
2009). Briefly, dried peptide was pretreated with neat trifluoroacetic
acid, distilled under nitrogen, washed with 1,1,1,3,3,3-hexafluoro-2propanol, distilled under nitrogen, and stored at ⫺20°C. The peptide was
diluted in DMSO to a final concentration of 200 M. In this form, A␤ is
in its monomeric form, but aggregates in culture medium (Gong et al.,
2003) into oligomeric A␤ species.
Primary astrocyte cultures. Murine cortical primary astrocytes were
cultured from postnatal day 2 pups. Cortices were dissected from the
brain, washed with HBSS, and treated with 0.25% trypsin/EDTA for 15
min at 37°C. Following trypsin digestion, the tissue was resuspended and
triturated in DMEM with 10% FBS and 100 U/ml penicillin/streptomycin. The cell suspension was then plated into T-75 flasks coated with
poly-D-lysine. The medium of the mixed glial cultures was changed every
3 d. Once the cells reached confluence, they were shaken at 180 rpm for
30 min to remove the microglial cells. The adherent cells were shaken at
240 rpm for an additional 6 h to remove the oligodendrocyte precursor
cells. The astrocyte-enriched cultures were then passed into 12-well
plates for experiments.
Plasmid construction, cell transfection, and lentivirus transduction.
Mouse TFEB cDNA containing an N-terminal-linked FLAG or Cerulean
fluorophore was cloned into a pAAV vector containing the CMV promoter (pAAV-CMV-FLAG-TFEB). For specific expression of TFEB in
astrocytes, a GFAP promoter (gfa2; Brenner et al., 1994) was used to drive
TFEB expression in AAV vector (pAAV-GFAP-FLAG-TFEB) or lentiviral vector (LV-GFAP-FLAG-TFEB). C17.2 neural progenitor cells were
transfected with pAAV-CMV-FLAG-TFEB or the control vectors using
Lipofectamine 2000 (Invitrogen) for 48 h and harvested for further analysis. For transduction of lentiviral vectors in astrocytes, the virus was
added to the cells (multiplicity of infection of 5) and incubated at 37°C
for 48 h. Fresh medium was then added and the cells were cultured for
8 –10 d before performing experimental assays, changing the medium
every 3 d. We observed ⬎90% efficiency for transfection or transduction
of exogenous TFEB (or GFP as control) in these in vitro studies.
Flow cytometry. C17.2 cells were incubated with LysoTracker Red (1
M) for 15 min and subjected to flow cytometry on FACScan instrument
(Becton-Dickinson). Cyflogic software (CyFlo) was used to analyze 20,000
events per run.
A␤ uptake and degradation. C17.2 cells were plated in 8-well chamber
slides, and 500 nM FAM-A␤42 was added for 1– 4 h. The cells were stained
with LysoTracker Red (100 nM) before confocal imaging. To quantify
uptake, synthetic A␤42 (500 nM) was applied to C17.2 cells and astrocytes
for varying times. The cells were washed with PBS three times,
trypsinized, and lysed in RIPA buffer. To quantify degradation, media
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containing A␤42 was removed and cells were thoroughly washed after 4 h
incubation. At varying times after washing, the cells were trypsinized and
lysed for ELISA. Bafilomycin A1 (100 nM) was added to the cells 30 min
before harvest to inhibit lysosome acidification.
Transferrin internalization. Transferrin uptake assay was performed as
described previously (Xiao et al., 2012). Briefly, primary astrocytes were
cultured in serum-free medium for 2 h, and then incubated with biotinylated transferrin (20 g/ml) in serum-free medium for 5 min at 37°C.
Cells were placed on ice, washed with ice-cold PBS, and then subsequently incubated three times for 10 min on ice in 25 mM MesNa, pH 5.0,
containing 150 mM NaCl and 50 M deferoxamine mesylate to remove surface bound transferrin. Cell lysate was immunoblotted with anti-biotin antibody (Cell Signaling Technology) to detect internalized transferrin.
Dextran uptake assay. Primary astrocytes were incubated with 70 kDa
dextran-TMR conjugate (10 M) for the indicated duration. Thereafter,
cells were washed thoroughly and trypsinized, followed by flow cytometric analysis with analysis of 20,000 events per run.
Animal model studies. B6C3-Tg (APPswe/PS1⌬E9)85Dbo/Mmjax
(also known as APP/PS1) transgenic mice, obtained from The Jackson
Laboratory (Jankowsky et al., 2004), were injected with AAV8 viral particles (generated by the Hope Center Viral Core at Washington University), as described previously (Xiao et al., 2012). For plaque load studies,
APP/PS1 mice were injected with 2 l of AAV8-GFAP-FLAG-TFEB or
AAV8-GFAP-eGFP (1.5 ⫻ 10 12 viral particles/ml) into bilateral hippocampi at 6 months of age. Mice were killed 4 months later. One hemisphere was fixed and coronal sections (50 m) were cut for histological
analysis (X-34 staining and HJ3.4 immunostaining). The other hemisphere was immediately dissected, snap frozen on dry ice, and stored at
⫺80°C for biochemical analysis (ELISA and Western blot). To detect the
A␤ level in predepositing mice, the abovementioned AAV viral vectors
were injected into the hippocampi of APP/PS1 mice at 3 months of age,
and the animals were killed 2 months later. All animal care and surgical
procedures were approved by the Animal Studies Committee of Washington University School of Medicine in accordance with guidelines of
the U.S. National Institutes of Health.
In vivo microdialysis. Two-month-old AAP/PS1 transgenic mice were
transduced in the hippocampus with AAV8-GFAP-FLAG-TFEB and
AAV8-GFAP-GFP particles, as above, and studied 4 weeks later by in vivo
microdialysis, as previously described (Cirrito et al., 2003, 2011). Briefly,
a guide cannula (BR-style; Bioanalytical Systems) was implanted and
cemented with the tip at coordinates: bregma –3.1 mm, midline ⫺2.5
mm, 1.2 mm below dura at a 12° angle. A 2 mm microdialysis probe was
then inserted into the hippocampus that contained a 38 kDa MWCO
semipermeable membrane (Bioanalytical Systems) allowing molecules
smaller than this cutoff to diffuse into the probe. A␤ capable of entering
the probe is dubbed “exchangeable A␤” (Cirrito et al., 2003). The probe
was flushed with 0.15% bovine serum albumin (Fisher Scientific) in an
artificial CSF perfusion buffer at a constant rate (1.0 l/min). The effluent was collected into a refrigerated fraction collector and assayed by
sandwich ELISA for A␤x-40 and A␤x-42 peptides at the end of each
experiment. All studies were initiated at the identical time of the day.
During microdialysis, animals were housed in specially designed cages to
permit free movement and ad libitum food and water while ISF A␤ was
being sampled. Baseline levels of ISF A␤ were sampled every 90 min
between hours 9 and 16 (after the microdialysis probe is inserted) and
averaged to determine the “baseline ISF A␤ level” in each mouse. Absolute in vivo concentration of ISF eA␤ for each mouse was determined by
correcting for the 20.8% recovery (1.0 l/min) as obtained by the interpolated zero flow method as described previously (Menacherry et al.,
1992; Cirrito et al., 2003). At hour 16 (t ⫽ 0), a ␥-secretase inhibitor
Compound E (200 nM reverse microdialysis; synthesized by AsisChem),
was administered directly to the hippocampus by adding the drug to the
microdialysis perfusion buffer. ISF A␤ was then sampled every 60 min for
an additional 6 h. This enabled measurement of the elimination half-life
of endogenous ISF A␤ in vivo similar to (Cirrito et al., 2003).
Immunohistochemistry. Sections were incubated in 0.3% H2O2 in Trisbuffered saline (TBS) for 10 min, washed with TBS, blocked with 3% dry
milk in TBS-X (0.25% Triton X-100 in TBS) for 1 h, and incubated with
HJ3.4 antibody (anti-A␤-1–13; Roh et al., 2012) overnight. A solution
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from Vectastain ABC kit (1:400) was applied to brain slices for 1 h,
followed by 0.025% 3–3⬘ diaminobenzidine tetrachloride in 0.25% NiCl
and 0.05% H2O2 for 10 –15 min. The slices were placed on glass slides,
dried overnight, dehydrated, and mounted. Images were obtained with
confocal microscope (Zeiss LSM).
X-34 plaque staining. Brain slices were mounted on SuperFrost Plus
slides, permeabilized with 0.25% Triton X-100 for 30 min, and stained
with X-34 (a generous gift from Robert Mach, Washington University)
dissolved in 40% ethanol and 60% water, pH 10, for 20 min. Tissue was
then thoroughly rinsed in PBS and mounted with Fluoromount mounting media.
Plaque quantification. Brain sections (50 m) were collected every 300
m from rostral anterior commissure to caudal hippocampus. Sections
were stained with X-34 or immunostained with HJ3.4 antibodies (n ⫽ 10
per group, 5 male and 5 female). Four slices per animal were used. NanoZoomer Digital Scanner (Hamamatsu Photonics) was used to create
high-resolution digital images of the stained brain slices. The total area of
plaque coverage in the hippocampus or piriform cortex (devoid of viral
transduction) was measured using NIH ImageJ software and expressed as
percentage total area for each slice. Results from n ⫽ 4 sections were
averaged to represent each animal.
Immunofluorescence. Fixed cells or paraffin-embedded brain sections
were washed with PBS, permeabilized with 0.3% Triton X-100 in PBS for
20 min, and blocked. For double labeling, a mixture of the following
antibodies was used: rabbit anti-FLAG (Sigma; 1:500), rat anti-LAMP1
(Santa Cruz Biotechnology; 1:50), mouse anti-TFEB (MyBioSource;
1:50), rabbit anti-TFEB (Bethyl Laboratories; 1:100), rabbit anti-GFAP
(Sigma; 1:100), rabbit anti- Iba1 (Wako Chemicals; 1:1000),and mouse
anti-NeuN (Sigma; 1:1000). A secondary antibody mixture of Alexa
Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 594conjugated goat anti-rat IgG (Invitrogen), or Cy3-conjugated donkey
anti-rabbit IgG (Jackson ImmunoResearch) and Alexa Fluor 488conjugated donkey anti-mouse IgG (Invitrogen) was applied. Cells or
sections were examined by confocal microscope (Zeiss LSM).
Stereological analysis. The sections were stained with 0.05% cresyl violet solution. The total neuron number in CA1 stratum pyramidale (sp)
and CA3 sp in the dorsal hippocampus was assessed using a computerbased stereology system (Stereo Investigator; MicroBrightField). Neuron
numbers were estimated with the optical fractionator (West et al., 1991).
Cresyl violet-stained cells were counted in four equally spaced 50 m
sections in the dorsal hippocampus of CA1 sp and CA3 sp, respectively.
Cresyl violet stained cells with nuclei imaged within the inclusive zone of
each dissector frame were counted. Results were reported in units of
density (cells per mm 3).
A␤ ELISA. A␤ in cell lysates from transfected C17.2 cells and transduced astrocytes were detected by sandwich ELISA, as previously described (Verges et al., 2011). To detect total A␤ in the hippocampus in
5-month-old mice, dissected tissue was sequentially homogenized in PBS
followed by RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton
X-100, 0.5% deoxycholate, 0.1% SDS, and 1⫻ protease inhibitor cocktail, to obtain detergent soluble A␤ at an age when plaques are not observed; Yan et al., 2009), and samples were pooled for analysis. In aged
mice (10 months old, when plaques are abundant), hippocampal tissues
were sequentially homogenized in PBS followed by 5 M guanidine in TBS,
pH 8.0 (to extract fibrillar and membrane bound A␤). For ELISA assays,
A␤x-40 and A␤x-42 peptides were captured with mouse monoclonalcoating antibodies HJ2 (anti-A␤35– 40) and HJ7.4 (anti-A␤37– 42) or
HJ5.1 (anti-A␤13–28), respectively (Kim et al., 2009). HJ5.1 (antiA␤13–28), a biotinylated antibody targeting the central domain, and
HJ3.5 (anti-A␤1–13, provided by Dr. David Holtzman, Washington
University School of Medicine, St. Louis, MO), which targets the
N-terminal amino acids, were used as the detecting antibody, followed by
streptavidin-poly-HRP-40 (Fitzgerald Industries). All ELISA assays were
developed using Super Slow ELISA TMB (Sigma) and absorbance read
on a Bio-Tek Epoch plate reader at 650 nm. Standard curves were
generated from synthetic human A␤1– 40 or A␤1– 42 peptides
(American Peptide).
Quantitative PCR. Real-time PCR was performed as described previously (Ma et al., 2012). Briefly, total RNA was prepared from transfected
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Table 1. Primer sequences employed for quantitative PCR analysis for indicated
murine genes
Gene

Forward (5⬘–3⬘)

Reverse (5⬘–3⬘)

LAMP1
CATHB
CATHD
ADAM17
ADAM10
BACE1
PSEN1
PEN2
LDLR
LRP1
APOE
APOJ
MMP2
MMP9
IDE
NEP
GAPDH

ACATCAGCCCAAATGACACA
AAATCAGGAGTATACAAGCATGA
CTGAGTGGCTTCATGGGAAT
AGGACGTAATTGAGCGATTTTGG
GTGCCAAACGAGCAGTCTCA
CAGTGGGACCACCAACCTTC
TGCACCTTTGTCCTACTTCCA
ATCTTGGTGGATTTGCGTTCC
CGCGGATCTGATGCGTCGCT
AACCCCTGCAGTGTCAACAA
CTGACAGGATGCCTAGCCG
GCCAGTGTGAAAAGTGCCAG
CCTGGACCCTGAAACCGTG
GGACCCGAAGCGGACATTG
TAATCCGGCCATCCAGAGAAT
GGCCTCCCTTCCAGAGACTA
ACTCCCACTCTTCCACCTTC

GGCTAGAGCTGGCATTCATC
GCCCAGGGATGCGGATGG
CCTGACAGTGGAGAAGGAGC
TGTTATCTGCCAGAAACTTCCC
ATTCGTAGGTTGAACTGTCTTCC
GCTGCCTTGATGGACTTGAC
GCTCAGGGTTGTCAAGTCTCTG
GCGCCAAACATAGCCTTTGATTT
CGGCCCTGGCAGTTCTGTGG
GGAGCGAGTCGTCTCTGATG
CGCAGGTAATCCCAGAAGC
GTTAGCCTGGGCAGGATTGT
TCCCCATCATGGATTCGAGAA
GAAGGGATACCCGTCTCCGT
CCAGCTCTAGTCCACGGTATT
ACGAATCAGTCTGGCCACAG
TCTTGCTCAGTGTCCTTGC

C17.2 cells or AAV-transduced hippocampus using an RNA-easy mini
kit (Qiagen), and cDNA was synthesized with 1 g of total RNA using
SuperScript III first-strand synthesis system (Invitrogen). One microliter
of cDNA template was mixed with 12.5 l of 2 ⫻ SYBR Green PCR
Master Mix (Invitrogen) and subjected to quantitative PCR in triplicate
under the following conditions: 50°C, 2 min; 95°C, 10 min; followed by
40 cycles of 95°C, 15 s; 60°C, 1 min in the ABI7500 Fast RealTime PCR
system. The housekeeping gene GAPDH was also amplified in parallel as
a reference for the quantification of transcripts. Primer sequences used
are shown in Table 1).
Cathepsin assay. Cathepsin activity was measured as described previously (Baldo et al., 2011) with slight modifications. Cell pellets or brain
tissues were homogenized in 100 mM sodium acetate, pH 5.5, with 2.5
mM EDTA, 0.01% Triton X-100, and 2.5 mM DTT. For the Cathepsin B
assay, the supernatant was incubated with 100 M Z-Arg-Arg-AMC
(Bachem) at pH 6.0. The fluorescent intensity of the cleavage product
was determined by excitation at 355 nm and emission at 460 nm using
kinetic readings in a TECAN Infinite M200 Pro microplate reader (Tecan),
and comparison was performed with a standard (7-amino-4methylcoumarin, AMC; AnaSpec). The Cathepsin D assay was performed at pH 4.0 by incubating the supernatant with 10 M substrate
7-methoxycoumarin-4-acetyl (Mca)-Gly-Lys-Pro-Ile-Leu-Phe-Phe-ArgLeu-Lys-2,4 nitrophenyl (Dnp)-D-Arg-NH2, with Mca-Pro-Leu-OH (Enzo
Life Sciences) as the standard; fluorescent intensity was determined with 320
nm excitation at 420 nm emission using the microplate reader.
Immunoblotting. Protein samples were run on 4 –12% Bis-Tris gels.
Blots were probed with the following antibodies: FLAG (1:1000), TFEB
(1:500), LAMP1 (1:500), Cathepsin B (Abcam; 1:500), Cathepsin D
(Santa Cruz Biotechnology; 1:200), low-density lipoprotein receptor
(LDLR; Novus; 1:500), LDL-receptor related peptide-1 (LRP1; Abcam;
1:500), and Actin (Sigma; 1:2000). Normalized band intensity was quantified using ImageJ software.
Statistical analysis. All data are shown as mean ⫾ SEM. Data were
analyzed by two-tailed Student’s t test for detecting significant differences between two groups. Differences among groups were analyzed by
one-way ANOVA followed by post hoc Tukey’s test. Differences were
deemed statistically significant at *p ⬍ 0.05 and **p ⬍ 0.01.

Results
Exogenous TFEB expression stimulates lysosome biogenesis
in neural cells, in vitro
Astrocytes take up A␤ and amyloid material for lysosomal degradation (Wyss-Coray et al., 2003; Koistinaho et al., 2004; Basak
et al., 2012), but age-related lysosome dysfunction is suspected to
underlie A␤ accumulation within astrocytes in elderly individuals (Funato et al., 1998) and in patients with AD (Nagele et al.,
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Figure 1. TFEB stimulates lysosome biogenesis and function. A, Representative confocal images demonstrating LysoTracker Red expression in Cerulean-tagged TFEB-transfected (Cer-TFEB)
C17.2 cells versus empty vector transfected controls. Representative of n ⫽ 4 independent experiments. B, Representative confocal images demonstrating LAMP1 expression in C17.2 cells
transfected with FLAG-tagged TFEB versus empty vector transfected controls. Representative of n ⫽ 4 experiments. C, Flow cytometric analysis of LysoTracker Red staining in cells transfected with
FLAG-tagged TFEB or empty vector (V; as control), with quantification of mean fluorescence expressed as fold over control (inset). N ⫽ 3/group. D, E, Immunoblots (D) and quantification (E) of
LAMP1 and Cathepsin B and D expression in cells transfected as in C. F, Cathepsin B and D activity in cells transfected as in C. N ⫽ 4/group; **p ⬍ 0.01.

2003). TFEB, a recently described basic helix-loop-helix transcriptional activator, stimulates lysosome biogenesis with activation of lysosomal degradative pathways (Sardiello et al., 2009;
Settembre et al., 2011, 2013b; Roczniak-Ferguson et al., 2012),
and cellular trafficking pathways (Medina et al., 2011; PeñaLlopis et al., 2011). Accordingly, we tested the hypothesis that
enhancing lysosomal degradative pathways in astrocytes by exogenous expression of TFEB will counter amyloid pathogenesis. To
confirm that TFEB stimulates lysosome biogenesis and function
in neural cells, we exogenously expressed murine TFEB in a
mouse neural progenitor C17.2 cell line (which can transdifferentiate into astrocytes; Zang et al., 2008), and examined lysosome
abundance, and expression and function of Cathepsin B and D,
which are two lysosomal enzymes implicated in A␤ catabolism
and AD pathogenesis (Sun et al., 2008; Butler et al., 2011; Schuur
et al., 2011; Yang et al., 2011; Avrahami et al., 2013). Exogenously
expressed Cerulean-tagged (Fig. 1A) or FLAG-tagged TFEB (Fig.
1B) localized to the nucleus indicating that it was transcriptionally active (Sardiello et al., 2009; Settembre et al., 2012) with an
increase in abundance of acidic organelles stained with LysoTracker Red (Fig. 1 A, C) or lysosome membrane protein, LAMP1
(Fig. 1B), indicating stimulation of lysosome biogenesis compared with the nontransfected cells. Exogenous expression of
TFEB also resulted in transcriptional upregulation of lysosomal
genes, LAMP1 and Cathepsin B and D (by 21, 26, and 34%,
respectively, over vector control; n ⫽ 4/group, p ⬍ 0.05). This
was associated with ⬎6-fold increase in TFEB protein expression
( p ⬍ 0.01, n ⫽ 3/group), and a 2- to 3-fold increase in expression
of LAMP1, Cathepsin B, and Cathepsin D proteins (Fig. 1 D, E).
An ⬃3-fold increase in Cathepsin B and D activity was observed
in TFEB transfected cells compared with controls (Fig. 1F ). Collectively, these results confirm that exogenous TFEB transcrip-

tionally upregulates lysosome abundance and stimulates activity
of lysosomal enzymes, in vitro.
Exogenous TFEB expression enhances A␤ uptake
and degradation
To determine the effect of TFEB on the kinetics of A␤ uptake and
its subcellular localization, C17.2 cells were transfected with
TFEB or empty vector and incubated with 500 nM FAM-labeled
A␤42 for increasing periods of time (1, 2, and 4 h) at 37°C. At
these time points, cells were imaged using confocal microscopy
with colabeling for LysoTracker Red, which is selectively taken up
in acidic vesicles, i.e., late endosomes and lysosomes (Sardiello et
al., 2009). Punctate intracellular A␤ was first apparent within 1 h,
and progressively increased thereafter (Fig. 2A), indicating that
FAM-A␤42 uptake was time dependent. Importantly, all intracellular FAM-A␤42 eventually localized to LysoTracker-stained
vesicles, suggesting that A␤ is taken up and trafficked into lysosomes. Notably, TFEB enhanced A␤ uptake with increased colocalization of A␤ with LysoTracker-stained organelles at all the
time points examined. To confirm these observations, we measured intracellular A␤ levels in C17.2 cells transfected with TFEB
or empty vector for 48 h, after application of A␤42 (500 nM) for
increasing periods of time (1, 2, 4, and 8 h). The cells were thoroughly washed and trypsinized to digest surface-bound A␤, followed by lysis, and intracellular A␤42 was quantified with ELISA.
Immunodetectable levels of intracellular A␤ levels progressively
increased in control transfected cells (Fig. 2B), as imaged above
(Fig. 2A). TFEB-transfected cells demonstrated significantly
higher levels of intracellular A␤42 compared with controls (Fig.
2B), suggesting faster rates of A␤ internalization. We next determined whether TFEB affects intracellular A␤ degradation. The
cells were incubated with A␤42 for 4 h and then thoroughly

Xiao et al. • Astrocytic TFEB Expression Enhances A␤ Clearance

J. Neurosci., July 16, 2014 • 34(29):9607–9620 • 9611

Figure 2. TFEB enhances A␤ uptake and degradation in C17.2 cells. A, Representative confocal images of C17.2 cells transfected with TFEB or empty vector, and incubated with 500 nM FAM-A␤42
at varying times, as indicated and imaged with LysoTracker Red colabeling. Representative of n ⫽ 3 independent experiments. B, C17.2 cells were transfected with TFEB or empty vector for 48 h,
and subsequently incubated with A␤42 (500 nM) for an additional 1– 8 h, and intracellular A␤42 was analyzed by ELISA at the time points indicated. N ⫽ 3/group per time point. C, C17.2 cells were
transfected with TFEB or empty vector for 48 h and A␤42 (500 nM) was applied for 4 h, followed by its removal. Cells were then thoroughly washed. At varying times after washing (as indicated), the
cells were trypsinized, lysed, and intracellular A␤42 was quantified by ELISA using two separate strategies. Specific antibodies used (refer to schematic, top) are noted (bottom). N ⫽ 3/group per
time point. D, Cells treated as in C with the addition of Bafilomycin A1 (100 nM) for 30 min before washing out the A␤ and cultured in its presence until the cells were collected for assay. N ⫽ 4/group;
*p ⬍ 0.05, **p ⬍ 0.01.

washed. At varying times thereafter, the cells were trypsinized (to
digest surface-bound A␤) and lysed for assessment of intracellular A␤ levels. Our results demonstrate that the rate of decline of
intracellular A␤ levels was significantly enhanced by TFEB expression compared with controls (Fig. 2C). This was reflected in
the shortened half-life (t(1/2)) in TFEB-transfected cells, and confirmed with an alternate A␤ peptide capture and detection strategy using distinct epitopes. These data suggest that TFEB
enhances both the uptake and complete degradation of A␤. To
determine whether TFEB-mediated elimination of A␤ proceeded
via lysosomal degradation, we cultured cells in the presence of
Bafilomycin A1, a proton pump inhibitor that blocks lysosome
acidification and impairs function (Yamamoto et al., 1998;
Mousavi et al., 2001), beginning 30 min before removal of A␤42
from the medium. Bafilomycin A1 treatment largely prevented

the decline in intracellular A␤42 levels (Fig. 2D), to the same
extent in both TFEB-transfected and control cells. These data
indicate that clearance of intracellular A␤ requires normal lysosome function, and TFEB enhances A␤ removal via stimulating
lysosomal function.
Recent studies have ascribed a prominent role for receptormediated uptake of A␤ via LDLR (Basak et al., 2012) and LRP1
(Kanekiyo et al., 2011; Verghese et al., 2013), as well as via macropinocytosis, a heparan sulfate proteoglycan-mediated process
(Kanekiyo et al., 2011). Therefore, to confirm whether TFEB accelerates A␤ uptake and degradation in astrocytes and to examine
the mechanisms involved, we lentivirally transduced primary
murine astrocytes with TFEB or GFP (as control) and examined
intracellular A␤ after incubation with A␤42 for 4 h in the presence of Dynasore (a dynamin-specific inhibitor of endocytosis),
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Figure 3. TFEB stimulates A␤ uptake and degradation in primary astrocytes. A, Percentage increase in A␤ uptake over a duration of 4 h in primary astrocytes transduced with TFEB over those
transduced with GFP (as control), in the presence of Dynasore (100 M), heparin (100 g/ml; ⬃18 U/ml), and vehicle (as control). N ⫽ 3 experiments. B, Transferrin uptake in primary astrocytes
transduced with TFEB or GFP (as control). N ⫽ 3/group. Dy, Dynasore. C, Flow cytometric analysis with representative tracings (top) and quantitation of mean fluorescence (bottom) for 70 kDa
dextran-TMR uptake in primary astrocytes transduced with TFEB or empty vector (as control) for the indicated duration. N ⫽ 4/group. D, Primary astrocytes were transduced with TFEB or GFP (as
control) and incubated with A␤ for 4 h, followed by washing and trypsinization. Intracellular A␤ levels were measured thereafter at T (time) ⫽ 0 and 1 h. Inset shows percentage reduction in A␤
levels over this duration. N ⫽ 3 experiments. E, F, Immunoblot and quantitation of LAMP1, LRP1, and LDLR expression in TFEB- transduced versus GFP-transduced primary astrocytes. N ⫽ 3/group;
*p ⬍ 0.05, **p ⬍ 0.01.

heparin (to antagonize heparan sulfate proteoglycans), or diluent
as control. As shown in Figure 3A, TFEB expression (⬃9-fold
over control; Fig. 3E) resulted in significantly increased intracellular A␤ levels compared with control transduced cells. This
increase was not affected by Dynasore treatment, but was significantly attenuated by heparin. Consistent with this observation,
we found that TFEB transduction did not upregulate transferrinreceptor endocytosis (which was inhibited by Dynasore treatment; Fig. 3B), but significantly upregulated the internalization
of 70 kDa dextran (Fig. 3C), which is known to occur via fluidphase macropinocytosis (Fan et al., 2007). Additionally, as observed with C17.2 cells (Fig. 2B), TFEB transduction
accelerated the decline in intracellular A␤ in primary astrocytes (Fig. 3D). Consistent with the observation of a lack of
effect of TFEB on endocytosis of A␤, we did not detect TFEBbinding CLEAR sites (Palmieri et al., 2011) in the promoters of
murine LDLR and LRP1, and TFEB did not affect their transcript levels (data not shown) or protein abundance (Fig.
3 E, F ). Importantly, TFEB induced upregulation of lysosomal
protein, LAMP1, in astrocytes indicating increased lysosomal
biogenesis, as observed in C17.2 cells (see above).These data
suggest that TFEB may accelerate A␤ uptake via heparan sulfate proteoglycan binding and macropinocytosis (Mandrekar
et al., 2009; Holmes et al., 2013).

AAV-mediated TFEB transduction in astrocytes induces
lysosome biogenesis and upregulates Cathepsin activity, in
vivo
Given the in vitro demonstration of TFEB-mediated enhancement of A␤ uptake and lysosomal degradation, we examined
whether enhancing the cellular degradative capacity of astrocytes,
in vivo, may be an effective strategy to reduce ISF A␤ levels and
attenuate plaque pathogenesis in AD. Indeed, astrocytes demonstrate intracellular accumulation of A␤-immunoreactive material in mouse models of AD, which may reflect a failure of
catabolism (Wyss-Coray et al., 2003). Enhancement of lysosomal
degradative capacity by exogenous TFEB expression may correct
this underlying defect, as was observed with diverse conditions of
lysosome dysfunction (Settembre et al., 2013a). To test this
premise, we used a viral gene transfer approach to target TFEB
expression to astrocytes in the hippocampus of 6-month-old
APP/PS1 mice, at a stage of early plaque deposition and growth
(Yan et al., 2009). N-terminal FLAG- tagged murine TFEB was
packaged in an AAV8 vector driven by a human GFAP promoter,
which was highly efficacious and specific in targeting astrocytes in
our previous studies (Kraft et al., 2013). AAV8 carrying a GFAP
promoter driving eGFP served as control. The viral particles were
stereotactically injected into bilateral hippocampi of 6-monthold APP/PS1 mice. The hippocampus was chosen for viral target-
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Figure 4. AAV8-mediated gene transfer of GFAP-promoter driven TFEB targets expression specifically to astrocytes. A, Representative fluorescence images of GFP expression in the hippocampus
of APP/PS1 mice injected with AAV8-GFAP-eGFP viral particles. Sequential images of brain sections confirm high transduction efficiency throughout the anterior hippocampus. B, Representative
confocal images demonstrating expression of TFEB (green) with GFAP (red, top), Iba-1 (red, middle), and NeuN (red, bottom) in the hippocampus of APP/PS1 mice injected with AAV8-GFAP-FLAGTFEB particles, demonstrating astrocyte-specific expression of TFEB. The boxed inserts (upper right corner) demonstrate magnified images of individual TFEB-labeled cells (arrows). DG, dentate
gyrus. C, D, Immunoblot and quantitation of APP, ␣-CTF, and ␤-CTF in AAV8-GFAP-FLAG-TFEB and AAV8-GFAP-eGFP transduced hippocampi. N ⫽ 3/group. E, Neuronal counts in the CA1 and CA3
layers of the hippocampi from AAV8-GFAP-FLAG-TFEB and AAV8-GFAP-eGFP transduced APP/PS1 mice and uninjected age- and sex-matched APP/PS1 mice as controls. N ⫽ 4/group.

ing because of its easily accessible location and its characteristic
and representative deposition of amyloid plaques (Yan et al.,
2009). Four months after injection (at 10 months of age), mice
were killed and assessed for efficacy of viral gene transfer. In
control brains, GFP was observed throughout the anterior hippocampus, spanning 3– 4 mm in the AP direction (Fig. 4A). The
FLAG-TFEB construct was selectively transduced to astrocytes in
the hippocampus, as assessed by colocalization of TFEB and

GFAP within cells demonstrating characteristic astrocytic morphology (Fig. 4B). Exogenous TFEB did not colocalize with Iba-1
(a microglial protein) or NeuN (a neuronal marker) demonstrating specificity of the targeting strategy (Fig. 4B). Consistent with
the lack of neuronal transduction, we did not observe alterations
in abundance of APP, its ␣-C-terminal fragment (␣-CTF), or the
␤-C-terminal fragment (␤-CTF), and no changes in transcript
levels coding for A␤ processing enzymes (ADAM17, ADAM10,
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Figure 5. AAV8-mediated astrocytic gene transfer of TFEB in astrocytes promotes lysosome biogenesis in APP/PS1 mice. A, Representative confocal images demonstrating expression
of FLAG (green) and LAMP1 (red) in hippocampal tissues transduced with AAV8-GFAP-FLAG-TFEB (bottom) and AAV8-GFAP-eGFP (top) viral particles. Arrow indicates individual
double-labeled cell shown under high magnification (insert, right upper corner). B, C, Immunoblots (B) with quantification (C) of lysosomal proteins in extracts from hippocampi
transduced with AAV8-GFAP-FLAG-TFEB or AAV8-GFAP-eGFP. N ⫽ 3/group. D, Cathepsin B and D activity in extracts from hippocampi transduced with AAV8-GFAP-FLAG-TFEB or
AAV8-GFAP-eGFP. N ⫽ 4/group; **p ⬍ 0.01.

BACE, PSEN1, and PEN2; data not shown) in AAV8-GFAPFLAG-TFEB transduced mice, compared with control. This
indicates a lack of effect of TFEB expression on APP processing (Fig. 4C,D). Additionally, we did not observe a difference
in neuronal counts in the hippocampus between TFEBtransduced, GFP-transduced, and uninjected APP/PS1 mice
(Fig. 4E). These data demonstrate a lack of toxicity with AAVmediated TFEB or GFP transduction strategy and the lack of
neuronal pathology in this mouse model of AD (APP/PS1
mice) at 10 months of age.
Exogenous TFEB localized to the nucleus of transduced astrocytes (Fig. 5A), indicating that it was transcriptionally “active”
(Settembre et al., 2011; Roczniak-Ferguson et al., 2012). AAVmediated transduction of TFEB resulted in a sixfold increase in
TFEB expression compared with controls ( p ⬍ 0.01, n ⫽
3/group; Fig. 5B), and increased LAMP1 expression (Fig. 5A–C),
consistent with stimulation of lysosome biogenesis, as observed
in vitro (Figs. 1A–E; 3C,D). Immunoblotting of hippocampal extracts confirmed a sixfold increase in LAMP1 and a twofold increase in Cathepsin B and D compared with controls (Fig. 5 B, C).
TFEB expression resulted in a dramatic increase of Cathepsin B
and D activity (Fig. 5D), indicating that exogenous TFEB stimulates lysosome function, in vivo.

Astrocytic TFEB expression reduces brain ISF A␤ half-life
and ISF A␤ concentration in vivo
The concentration of soluble A␤ in the extracellular space (ISF)
reflects a steady state determined by the rates of A␤ generation
and elimination (Cirrito et al., 2003). Given that A␤ peptides are
primarily generated within neurons then secreted into the ISF
(Hartmann et al., 1997; Kamenetz et al., 2003), and AAVtransduced TFEB was expressed selectively in astrocytes by design, we postulated that enhanced astrocytic TFEB expression
will stimulate uptake and degradation of A␤, in vivo, similar to
that observed in vitro (Fig. 2). Accordingly, we transduced
2-month-old APP/PS1 mice with AAV8-GFAP-FLAG-TFEB and
control AAV8-GFAP-eGFP viral particles to determine whether
astrocytic TFEB expression impacts ISF A␤. These studies were
performed before the deposition of plaques (Yan et al., 2009) to
determine the role of astrocytic TFEB in normal A␤ metabolism
without the complicating factor of deposited A␤. We performed
in vivo microdialysis to ascertain A␤ levels in the ISF 1 month
after viral injection (Fig. 6A). TFEB-expressing mice had significantly lower steady-state concentration of ISF A␤ (by 39%) compared with control mice (Fig. 6 A, C). After steady-state measures
of ISF A␤ were obtained, mice were administered the potent
␥-secretase inhibitor, Compound E (Cirrito et al., 2011), and ISF
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Figure 6. AAV8-mediated astrocytic gene transfer of TFEB reduces brain ISF A␤ levels and reduces in vivo A␤ half-life. A, Assessment of A␤ levels by in vivo microdialysis in 3-month-old APP/PS1
mice transduced with AAV8-GFAP-FLAG-TFEB (TFEB) and AAV8-GFAP-eGFP (GFP) with serial hourly measurements. N ⫽ 5 mice/group. At t ⫽ 0, mice were continually administered Compound E
directly to the hippocampus (200 nM, reverse microdialysis) followed by hourly sampling for A␤. Mean absolute in vivo “exchangeable” A␤ (eA␤x-40) concentration was averaged over a 9 h period
before drug administration, and assessed to be 362.4 ⫾ 49.0 pg/ml in TFEB-transduced mice versus 592.5 ⫾ 46.9 pg/ml in controls. B, Semi-log plot of decline in percentage basal ISF A␤ levels
during administration of Compound E, in animals in A. Half-life in control mice was 1.26 ⫾ 0.11 h and 0.76 ⫾ 0.06 h in TFEB-expressing mice. C, Quantification of averaged concentration and
elimination half-life of ISF A␤ as calculated in A and B; **p ⬍ 0.01. D, E, A␤40 and A␤42 levels in dissected hippocampal tissues from AAV8-GFAP-FLAG-TFEB (TFEB) and AAV8-GFAP-eGFP (GFP)
transduced APP/PS1 mice (5 months of age). Tissue was homogenized first in PBS (D) and then in RIPA (E) quantified with ELISA assay. HJ2 and HJ7.4 antibodies were used for capture A␤40 and
A␤42, respectively, and HJ5.1 antibody was used for detection. N ⫽ 5 mice/group; *p ⬍ 0.05, **p ⬍ 0.01.

was sampled for an additional 6 h to determine the elimination
rate (half-life) of pre-existing A␤ (Fig. 6A). As shown, the elimination of ISF A␤ followed first-order kinetics in both control and
TFEB-expressing mice (Fig. 6B). Astrocytic expression of TFEB
significantly reduced the in vivo elimination half-life of ISF A␤ by
40%, compared with controls (Fig. 6 B, C), mirroring the magnitude of half-life reduction in in vitro studies (Fig. 2C). To confirm
that the reduction in ISF A␤ levels with astrocytic TFEB expression resulted in increased A␤ elimination, and not merely increased cellular uptake, we assessed total A␤ abundance in
hippocampal tissue and observed a significant reduction in total
immunodetectable A␤ levels in TFEB-transduced hippocampi
(by ⬃40% vs control, at this time point; Fig. 6 D, E). This directly
demonstrates that exogenous TFEB expression in astrocytes enhances A␤ degradation, in vivo.
We did not observe any significant difference in transcript
levels for A␤-binding receptors (LRP1, LDLR), chaperones
(ApoE, Apo J), or A␤ metabolizing enzymes (MMP2, MMP9,
IDE, or Neprilysin) in the AAV-TFEB transduced hippocampi

compared with controls (data not shown), suggesting that astrocytic TFEB expression does not alter the extracellular degradation
or transport of A␤ peptides. These observations are consistent
with enhanced cellular uptake and degradation of A␤ by TFEBtransduced astrocytes, in vivo, as observed in vitro (Figs. 2, 3).
Astrocytic TFEB expression reduces total A␤ levels and
amyloid plaque load in APP/PS1 mice
To evaluate the effect of astrocytic TFEB expression on A␤ levels
and amyloid accumulation in aging mice, hippocampal tissue
from the 10-month-old mice was sequentially homogenized in
PBS followed by guanidine to extract PBS-soluble and -insoluble
fractions (Yan et al., 2009). Each fraction was quantified using
ELISAs to measure both A␤40 and A␤42. Exogenous TFEB expression resulted in a decrease in both PBS-soluble and insoluble
fractions of A␤40 and A␤42 (Fig. 7 A, B), to a comparable extent
as observed in the ISF (Fig. 6 A, C) and in the hippocampi from
TFEB-transduced predepositing APP/PS1 mice (Fig. 6 D, E). Importantly, expression of GFAP promoter-driven GFP used as
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control for these studies did not result in
altered A␤ levels compared with uninjected age- and sex-matched mice (data
not shown). These data indicate that exogenous TFEB enhanced both uptake and
degradation of A␤ within astrocytes, in
vivo.
To determine whether TFEB-mediated
decline in ISF A␤ influences amyloid
plaque pathogenesis, we stained brain
slices with X-34 to assess compact amyloid plaques and immunostained with
anti-A␤ antibodies to assess A␤ plaque
load. Quantitative analysis of X-34 staining (Fig. 7C) demonstrated that amyloid
plaque load in TFEB-transduced hippocampus was significantly decreased
(Fig. 7 D, E) compared with control. This
reduction was anatomically localized to
the hippocampus (see area enclosed
within dotted line), which was the site of
experimental TFEB transduction, without
an effect on cortical plaque load (Fig. 7D),
consistent with a local effect of enhanced
astrocyte A␤ uptake and degradation. In
addition, TFEB-stimulated reduction in
plaque load was similar in magnitude
in both sexes (Fig. 7E; n ⫽ 5 mice/sex/
group), despite a higher plaque load observed in female mice, as previously
described (Callahan et al., 2001). Similarly, TFEB-transduced hippocampi (but
not the cortex) demonstrated significantly
reduced A␤-immunostained plaque load
(Fig. 7F–H ) compared with control. The
reduction in amyloid plaque load with
TFEB expression (by ⬃45%) is consistent
with the magnitude of decline in ISF A␤
levels (by 40%), mirroring previous observations, suggesting a robust effect of increased A␤ removal from the extracellular
space on reducing amyloid plaque load
(Yan et al., 2009). Collectively, these
results indicate that astrocytic TFEB expression attenuates amyloid plaque accumulation, likely via enhancing A␤ uptake
from the ISF and facilitating clearance via
lysosomal degradation, in the brain.
4

Figure 7. Astrocytic TFEB overexpression decreases amyloid plaque load in hippocampus of APP/PS1 mice. A, B, A␤40 and
A␤42 levels in dissected hippocampal tissues from AAV8-GFAP-FLAG-TFEB (TFEB) and AAV8-GFAP-eGFP (GFP) transduced mice
(10 months of age). Tissue was homogenized first in PBS (soluble levels, A), then in 5 mM guanidine (insoluble levels, B) quantified

with ELISA assay. HJ2 and HJ7.4 antibodies were used for capture A␤40 and A␤42, respectively, and HJ5.1 antibody was
used for detection. N ⫽ 8 mice/group; **p ⬍ 0.01. C, Representative X-34-stained images from APP/PS1 mice treated as
in A. The area of the hippocampus is outlined with a dotted
line. D, E, Quantification of X-34-stained plaque burden in the
hippocampus in mice treated as in A (D) and plaque burden
stratified by sex (E). N ⫽ 10 (5 male and 5 female) mice/
group. F, Representative A␤-immunostained images from
mice treated as in A. G, H, Quantification of A␤-stained plaque
burden in the hippocampus in mice treated as in A (G) and
plaque burden stratified by sex (H). N ⫽ 10 (5 male and 5
female) mice/group; *p ⬍ 0.05, **p ⬍ 0.01.

Xiao et al. • Astrocytic TFEB Expression Enhances A␤ Clearance

Discussion
We have demonstrated that targeted gene delivery of TFEB to
astrocytes is effective in countering amyloid plaque pathogenesis.
Specifically, astrocytic TFEB expression in the hippocampus (6to 9-fold above basal level) resulted in TFEB activation (localization to the nucleus) and induction of the lysosomal machinery,
including enhanced Cathepsin B and D activity (Figs. 1, 4, 5).
TFEB also stimulated A␤ uptake and degradation via lysosomes
(Figs. 2, 3), resulting in significantly lower A␤ levels (Figs. 6, 7)
and shortened A␤ half-life, both intracellularly as observed in
vitro (Fig. 2) and extracellularly in the ISF (Fig. 6). This resulted in
a substantial attenuation in amyloid plaque load (Fig. 7) in the
hippocampus of APP/PS1 mice. These observations point to a
direct effect of TFEB on stimulating A␤ degradation by astrocytes
to attenuate amyloid plaque pathogenesis.
Astrocytes play a critical role in maintaining neuronal homeostasis by providing energy, eliminating waste, regulating transport across the blood– brain barrier, clearing neurotransmitters
at the synapse, regulating cellular ionic fluxes, and mediating
repair in response to injury (Eroglu and Barres, 2010). Moreover,
astrocytes provide complete coverage of brain parenchyma by
virtue of their territorial relationships, forming a mosaic with
adjacent astrocytes (Bushong et al., 2002). Thus, astrocytes are
well positioned both metabolically and anatomically to play an
important homeostatic role under basal conditions and during
disease pathogenesis. A prominent role for astrocytes in AD
pathogenesis is evidenced by astrocyte activation early in the disease process (Schipper et al., 2006; Owen et al., 2009; Carter et al.,
2012) together with their ability to take up and degrade A␤
(Wyss-Coray et al., 2003; Koistinaho et al., 2004; Nielsen et al.,
2009). These observations suggest that while astrocytes may participate in physiologic clearance of A␤ peptides to maintain their
steady-state levels in the extracellular fluids in normal individuals
(Bateman et al., 2006), their role in the removal of extracellular
A␤ and amyloid material may be insufficient in the setting of AD
(Wyss-Coray et al., 2003; Nielsen et al., 2009). Our results indicate that the ability of astrocytes to eliminate amyloid material
may be enhanced or restored by stimulating TFEB-mediated trafficking and degradative pathways, as a therapeutic and/or preventive strategy in individuals predisposed to developing AD.
Astrocytes take up A␤ bound to membrane receptors such as
LDLR (Basak et al., 2012) or LRP1 (Verghese et al., 2013) via
endocytosis. Multiple studies have demonstrated the efficacy of
enhancing cellular uptake and degradation by overexpressing
these receptors (Kim et al., 2009; Basak et al., 2012; Castellano et
al., 2012). Glial cells may also take up A␤ bound to heparan
sulfate proteoglycans by macropinocytosis (Mandrekar et al.,
2009), involving invagination of the cell membrane to engulf
extracellular material. In addition, activated astrocytes with hypertrophied processes exist in close contact with amyloid
plaques, and have been postulated to phagocytose amyloid material (Funato et al., 1998; Wyss-Coray et al., 2003). Our data
indicate that TFEB stimulates uptake of A␤ via heparan sulfate
proteoglycans and macropinocytosis without affecting the A␤binding receptors and endocytosis. The underlying molecular
mechanisms for this observation warrant further exploration.
We and others have observed that A␤ is rapidly trafficked to
the lysosomes after uptake (Kanekiyo et al., 2011; Basak et al.,
2012) and exogenous TFEB accelerates this process. Degradation
of A␤ requires intact lysosome function. Indeed, normal lysosome function in astrocytes is essential to prevent neurodegeneration, as targeted astrocytic ablation of sulfatase-modifying
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factor 1 (loss of function causing multiple sulfatase deficiencies),
provokes degeneration of cortical neurons (Di Malta et al., 2012).
Emerging evidence has fostered suspicion that aging-induced impairment in lysosome function facilitates pathogenesis in AD
(Nixon and Cataldo, 2006; Wolfe et al., 2013). While it remains to
be determined whether a specific impairment in astrocytic lysosome function causes or contributes to amyloid plaque deposition, our data indicate that upregulation of lysosomal numbers
and enhanced lysosome function with TFEB-induced lysosome
biogenesis (Settembre et al., 2011) is highly efficacious in facilitating A␤ and amyloid plaque elimination by astrocytes.
We have also found that exogenous TFEB expression results in
increased abundance and activity of Cathepsin B and D, both in
vitro and in vivo, which is likely involved in A␤ degradation.
Evidence suggests that Cathepsin activity is essential for maintaining normal levels of A␤ in the extracellular space, as germline
ablation of Cathepsin B increases A␤ levels and worsens plaque
deposition (Mueller-Steiner et al., 2006). Lentiviral transduction
of Cathepsin B (Mueller-Steiner et al., 2006) or germline ablation
of endogenous protease inhibitors such as cystatin C (Sun et al.,
2008) and B (Yang et al., 2011) increases Cathepsin activity, reduces A␤ levels, and attenuates plaque deposition. Polymorphisms in the gene coding for Cathepsin D have been implicated
in conferring increased risk for developing AD (Schuur et al.,
2011), and Cathepsin D activity, reduced in AD mouse models
(Avrahami et al., 2013), may be pharmacologically stimulated
with inhibition of glycogen synthase kinase-3␤ (GSK3␤) to attenuate amyloid plaque pathogenesis. Aside from the specific induction of Cathepsin B and D, it is likely that other Cathepsins are
induced (Palmieri et al., 2011) and mediate a general increase in
lysosomal degradation.
Among other plausible subcellular mechanisms that may underlie TFEB-induced reduction in A␤ levels, enhanced lysosomal
acidification by transcription of the lysosomal proton pump machinery (Settembre et al., 2011; Roczniak-Ferguson et al., 2012)
may be highly relevant. Indeed, TFEB expression may rectify the
impaired acidification of lysosomes with aging (Wolfe et al.,
2013), or with loss of presenilin, as observed in familial AD (Lee et
al., 2010). TFEB also stimulates lysosomal calcium release
(Medina et al., 2011) and promotes autophagosome–lysosome
fusion (Settembre et al., 2011), which may be other mechanisms
whereby TFEB may correct the lysosomal calcium storage and
release defects observed with presenilin deficiency (Coen et al.,
2012). The synergistic effect of these multiple TFEB-stimulated
mechanisms may be to promote complete proteolysis of A␤ and
prevent aggregation into fibrils in an acidic environment (Hu et
al., 2009), in the setting of underlying impairment in lysosome
function.
Astrocytes are “activated” (displaying hypertrophied processes and increased GFAP expression) surrounding amyloid
plaques in humans with AD (Schipper et al., 2006; Owen et al.,
2009; Carter et al., 2012) and in APP transgenic mouse models
(Nagele et al., 2003; Wyss-Coray et al., 2003; Nielsen et al., 2009).
Activated astrocytes are observed in virtually all neurodegenerative diseases. In some, it has been suggested that astrocyte activation may be protective, as impairment in astrocyte activation
with targeted ablation of intermediate filament proteins, GFAP
and vimentin, worsens the pathology in neuronal ceroid lipofuscinosis, a lysosomal storage disease (Macauley et al., 2011). Importantly, we have observed that activated astrocytes play a
critical role in attenuating plaque pathogenesis (Kraft et al.,
2013). TFEB may stimulate astrocyte activation and phagocytosis
of amyloid material via its upregulation of the phagocytotic ma-
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chinery (Palmieri et al., 2011), an activity that warrants further
investigation.
Reduced TFEB activation may underlie aging-related impairment in lysosomal function in AD (Nixon and Cataldo, 2006;
Wolfe et al., 2013), a premise that needs further exploration.
Indeed, insufficient TFEB activity has been implicated in causing
lysosomal dysfunction in models of Parkinson’s disease and
AAV-mediated transduction of TFEB accelerated clearance of
␣-synuclein and protection against cytotoxicity (Decressac et al.,
2013). Activation of mTOR, which provokes phosphorylation
and cytoplasmic retention of TFEB in diverse cell types (Zoncu et
al., 2011; Settembre et al., 2012; Martina and Puertollano, 2013),
is observed in AD mouse models (Lafay-Chebassier et al., 2005).
Various studies have demonstrated attenuation of plaque pathology with pharmacological inhibition of mTOR and GSK3␤ (Cai
et al., 2012; Avrahami et al., 2013) or administration of lysosomal
modulator Z-Phe-Ala-diazomethylketone (Butler et al., 2011).
Activation of TFEB with GSK3␤ inhibition in neural tissue indicates the need to examine the therapeutic efficacy of TFEB targeting to various cell types in countering AD pathogenesis. Although
small molecules that enhance TFEB expression have not been
extensively explored, a recent study suggests that identification of
such agents may be feasible (Song et al., 2014). Further studies are
also needed to examine possible adverse effects of targeting TFEB
activity, but current studies do not reveal obvious adverse effects
(Tsunemi et al., 2012; Decressac et al., 2013).
A major strength of our viral gene transfer approach is the
rapid assessment of cellular and molecular mechanisms involved
in amyloid plaque pathogenesis, exploiting regional differences
(targeting hippocampus) in cell-autonomous effects to establish
specificity of targeting TFEB in astrocytes. However, focal targeting of TFEB expression to the hippocampus precludes an evaluation of its effects on cognitive parameters or neuronal
pathology, which is not observed in the APP/PS1 model. Notwithstanding these limitations, our data demonstrate that TFEB
activation enhances A␤ uptake and degradation in astrocytes,
thereby lowering ISF A␤ concentrations and resulting in decreased plaque load. This study lays the foundation for exploring
therapeutic strategies targeting TFEB activation, either pharmacologically or via gene therapy, both globally and in specific cell
types, to counter AD pathogenesis.
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